Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - Asterion Cannabis Inc. ("Asterion" or the "Company"), announces a brokered private placement of up to 6,666,667 units (each, a "Unit") at the price of CAD$1.50 per Unit, for aggregate gross proceeds of up to CAD$10,000,000 (the "Financing"). Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one half a common share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder thereof to purchase one additional Share at a price of CAD$2.00 per Share for a period of 24 months from the closing of the Financing, subject to acceleration. All securities issued under the Financing will be subject to a hold period of four months and one day in Canada.
The Company has engaged First Penny Investments Pty Ltd ("First Penny") as the agent for this financing. First Penny is an Australian advisory firm with a global footprint in merchant banking that helps maximize the potential of emerging and high growth companies through the execution of business and capital strategy and the forming of strategic relationships. First Penny Investments is the authorized representative of AFSL License number 230680.
Proceeds from the Financing are intended to be used for:
- Pre-construct costs for the approximately 40 hectares (99 acres) of cutting-edge, secure, purpose-built greenhouses in Queensland, Australia, to produce high-quality medicinal cannabis (the "Queensland Facility"). For more information on the Queensland Facility, see news release dated April 24, 2019;
- The execution of the Company's early revenue strategic plan;
- Listing the Company's shares on a recognized stock exchange; and
- General working capital purposes.
Asterion's Chairman and CEO, Mr. Stephen Van Deventer, commented, "We are very excited to be working with First Penny Investments in securing equity funding for this pre-construction phase. With this funding, we will be able to implement our early revenue plan, complete the pre-construction requirements and start the IPO process."
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States, or in any jurisdiction in which such an offer or sale would be unlawful. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any United States state securities laws, and may not be offered or sold in the United States or to the account or benefit of a "U.S. person" (as defined in Regulation S under the 1933 Act) or a person in the United States absent registration or an applicable exemption from the registration requirements.
Asterion Cannabis Inc. is a Canadian medicinal cannabis company with a wholly-owned Australian subsidiary, Asterion (Australia) Pty Ltd. With its cultivation to market strategy, the Company's focus is leading and advancing cannabis agriculture, producing the highest quality, low cost, genetically uniform cannabis strains and cannabinoid products for global supply. The Australian government formally recognizes the Company with a Major Project Status, and the Company has been granted a medicinal cannabis license, a cannabis research license, and a manufacture license from the Australian Office of Drug Control.
Led by a highly experienced team with over 200 years of combined relevant credentials spanning - North America, Europe, the Middle East, and Asia-Pacific. Management experience with large scale projects includes medicinal cannabis, renewable energy, and capital markets.
On Behalf of the Board of Directors
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
For private placement information, please contact:
First Penny Investments
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the amount of the Financing, the intended use of proceeds of the Financing, the construction of the Queensland Facility and the Company's anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes", "estimates" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including that market fundamentals, will result in sustained demand and prices for medicinal cannabis products, the receipt of any necessary permits, licenses and regulatory approvals in connection with the construction of the Queensland Facility in a timely manner, the availability of financing on suitable terms for the construction and continued operation of the Company's business, and the Company's ability to comply with environmental, health and drugs laws and retain and attract qualified personnel.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the inability of the Company to, among other things, secure investor interest in the Financing, obtain the required approvals for the construction and operation of the Queensland Facility, and the inability of the Company to execute its proposed business plans and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions, future prices of cannabis, changes in the financial markets and in the demand and market price for cannabis, or changes in laws, regulations and policies affecting the biotechnology or medical cannabis industry and delays in obtaining governmental and regulatory approvals including for the Queensland Facility, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
**NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES**
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57160
News Provided by Newsfile Corp.